For all the hype surrounding weight loss drugs GLP-1 Wegoffy and ZibondThese medications do not work for everyone. Approximately 17% of people taking these medications are considered “non-responders,” leaving them looking for a different solution. But there’s an interesting new drug waiting in the wings. Although it has not yet been approved by the Food and Drug Administration (FDA), people are already researching it.
It’s called retatrotide, and it’s a triple-agonist drug, which means it works on three different receptors in the body. In comparison, Wegovy (semaglutide) acts on one receptor, while Zepbound (tirzepatide) acts on two receptors.
Retatrutide has already been hailed as Game changer In a field of health that has already welcomed a lot of great medicines in the past few years. In reality, Clinical trial results It has been shown to be so effective for weight loss that some people have dropped out of trials because they felt they had lost too much weight.
But retaretide is still being tested in clinical trials. Eli Lilly, which makes reatrutide and Zepbound, has not yet submitted trial results to the US Food and Drug Administration for approval. So this is still an experimental drug, and copies of it are sold online for cheap.
Mir Ali, MDmedical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, California, tells SELF that retreotide “isn’t really available” for use yet, other than enrolling in a clinical trial. There is no set timeline for when it will be on the market, since clinical trial results have not yet been submitted to the FDA.
If you have struggled with Weight loss on GLP-1 medication Or you just want to pay a lot less for what seems to be the next big thing in weight loss drugs, it’s understandable that you’d be tempted to add this to your cart. That’s why doctors recommend resisting the urge.
What is retatrotide?
Retatrotide is similar to GLP-1 drugs in several ways. That is, it is used to lose weight and is given once a week by injection. He loves WegsOzempic, Zepbound, and retatrutide work to reduce appetite and slow digestion.
But retatrutide occurs more than that. This medication acts on three hormone receptors in the body – glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP), and glucagon (GCG). “This is the first device in the pipeline that works on three different receptors,” says Dr. Ali. “The theory is that the more receptors a drug affects, the more effective the drug is.”
